Fetal	O
skin	O
as	O
a	O
pro	O
-	O
inflammatory	O
organ	O
:	O
Evidence	O
from	O
a	O
primate	B-OG
model	O
of	O
chorioamnionitis	B-DS

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Background	O

Intrauterine	B-DS
infection	I-DS
is	O
a	O
primary	O
cause	O
of	O
preterm	O
birth	O
and	O
fetal	O
injury	O
.	O

The	O
pro	O
-	O
inflammatory	O
role	O
of	O
the	O
fetal	O
skin	O
in	O
the	O
setting	O
of	O
intrauterine	B-DS
infection	I-DS
remains	O
poorly	O
characterized	O
.	O

Whether	O
or	O
not	O
inflammation	O
of	O
the	O
fetal	O
skin	O
occurs	O
in	O
primates	B-OG
remains	O
unstudied	O
.	O

Accordingly	O
,	O
we	O
hypothesized	O
that	O
:	O
i	O
)	O
the	O
fetal	O
primate	B-OG
skin	O
would	O
mount	O
a	O
pro	O
-	O
inflammatory	O
response	O
to	O
preterm	O
birth	O
associated	O
pro	O
-	O
inflammatory	O
agents	O
(	O
lipopolysaccharides	O
from	O
Escherichia	B-OG
coli	I-OG
,	O
live	O
Ureaplasma	B-OG
parvum	I-OG
,	O
interleukin	B-GP
-	I-GP
1β	I-GP
)	O
and	O
;	O
ii	O
)	O
that	O
inhibiting	O
interleukin	B-GP
-	I-GP
1	I-GP
signaling	O
would	O
decrease	O
the	O
skin	O
inflammatory	O
response	O
.	O

Methods	O

Rhesus	B-OG
macaques	I-OG
with	O
singleton	O
pregnancies	O
received	O
intraamniotic	O
injections	O
of	O
either	O
sterile	O
saline	O
(	O
control	O
)	O
or	O
one	O
of	O
three	O
pro	O
-	O
inflammatory	O
agonists	O
:	O
E	B-OG
.	I-OG
coli	I-OG
lipopolysaccharides	O
,	O
interluekin	B-GP
-	I-GP
1β	I-GP
or	O
live	O
U	B-OG
.	I-OG
parvum	I-OG
under	O
ultrasound	O
guidance	O
.	O

A	O
fourth	O
group	O
of	O
animals	B-OG
received	O
both	O
E	B-OG
.	I-OG
coli	I-OG
lipopolysaccharide	O
and	O
interleukin	B-GP
-	I-GP
1	I-GP
signaling	O
inhibitor	O
interleukin	B-GP
-	I-GP
1	I-GP
receptor	I-GP
antagonist	O
(	O
Anakinra	O
)	O
prior	O
to	O
delivery	O
.	O

Animals	B-OG
were	O
surgically	O
delivered	O
at	O
approximately	O
130	O
days	O
’	O
gestational	O
age	O
.	O

Results	O

Intraamniotic	O
lipopolysaccharide	O
caused	O
an	O
inflammatory	O
skin	O
response	O
characterized	O
by	O
increases	O
in	O
interluekin	B-GP
-	I-GP
1β	I-GP
,-	O
6	O
and	O
-	O
8	O
mRNA	O
at	O
16	O
hours	O
.	O

There	O
was	O
a	O
modest	O
inflammatory	O
response	O
to	O
U	B-OG
.	I-OG
parvum	I-OG
,	O
but	O
interleukin	B-GP
-	I-GP
1β	I-GP
alone	O
caused	O
no	O
inflammatory	O
response	O
in	O
the	O
fetal	O
skin	O
.	O

Intraamniotic	O
Anakinra	O
treatment	O
of	O
lipopolysaccharide	O
-	O
exposed	O
animals	B-OG
significantly	O
reduced	O
skin	B-DS
inflammation	I-DS
.	O

Conclusions	O

Intraamniotic	O
lipopolysaccharide	O
and	O
U	B-OG
.	I-OG
parvum	I-OG
were	O
associated	O
with	O
modest	O
increases	O
in	O
the	O
expression	O
of	O
inflammatory	O
mediators	O
in	O
primate	B-OG
fetal	O
skin	O
.	O

Although	O
administration	O
of	O
Interleukin	B-GP
-	I-GP
1β	I-GP
alone	O
did	O
not	O
elicit	O
an	O
inflammatory	O
response	O
,	O
lipopolysaccharide	O
-	O
driven	O
skin	B-DS
inflammation	I-DS
was	O
decreased	O
following	O
intraamniotic	O
Anakinra	O
therapy	O
.	O

These	O
findings	O
provide	O
support	O
for	O
the	O
role	O
of	O
the	O
fetal	O
skin	O
in	O
the	O
development	O
of	O
the	O
fetal	O
inflammatory	O
response	O
.	O

Introduction	O

Preterm	O
birth	O
(	O
delivery	O
before	O
37	O
weeks	O
’	O
gestation	O
)	O
is	O
implicated	O
in	O
more	O
than	O
1	O
million	O
perinatal	O
deaths	O
worldwide	O
each	O
year	O
[	O
1	O
].	O

Fetal	O
and	O
intrauterine	O
inflammation	O
cause	O
preterm	O
labor	O
,	O
and	O
the	O
presence	O
of	O
a	O
systemic	O
fetal	O
inflammatory	O
response	O
at	O
delivery	O
is	O
also	O
associated	O
with	O
increased	O
risk	O
of	O
adverse	O
neonatal	O
respiratory	O
and	O
central	O
nervous	O
system	O
outcomes	O
[	O
2	O
].	O

Identifying	O
the	O
gestational	O
tissues	O
responsible	O
for	O
generating	O
intrauterine	O
inflammation	O
is	O
thus	O
an	O
important	O
step	O
in	O
advancing	O
both	O
our	O
understanding	O
of	O
the	O
aetiology	O
of	O
preterm	O
birth	O
and	O
in	O
the	O
development	O
of	O
potential	O
anti	O
-	O
inflammatory	O
interventions	O
.	O

A	O
large	O
literature	O
describes	O
the	O
pro	O
-	O
inflammatory	O
responses	O
of	O
the	O
fetal	O
lung	O
and	O
the	O
chorioamnion	O
to	O
pro	O
-	O
inflammatory	O
stimulation	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
fetal	O
skin	O
in	O
driving	O
intrauterine	O
and	O
fetal	O
inflammation	O
is	O
less	O
clear	O
.	O

The	O
fetal	O
skin	O
is	O
a	O
large	O
and	O
highly	O
vascularized	O
immunologically	O
competent	O
organ	O
[	O
3	O
,	O
4	O
]	O
that	O
is	O
continuously	O
exposed	O
to	O
amniotic	O
fluid	O
in	O
utero	O
.	O

Amniotic	O
fluid	O
can	O
contain	O
pathogenic	O
microorganisms	O
[	O
5	O
]	O
and	O
proinflammatory	O
mediators	O
associated	O
with	O
preterm	O
labor	O
and	O
delivery	O
including	O
interleukins	B-GP
(	B-GP
IL	I-GP
)-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
and	O
tumour	B-GP
necrosis	I-GP
factor	I-GP
(	B-GP
TNF	I-GP
)-	I-GP
α	I-GP
[	O
2	O
,	O
6	O
,	O
7	O
].	O

Amniotic	O
contents	O
thus	O
can	O
interact	O
with	O
fetal	O
skin	O
by	O
direct	O
exposure	O
,	O
with	O
the	O
fetal	O
gut	O
epithelium	O
by	O
swallowing	O
,	O
and	O
the	O
fetal	O
lung	O
by	O
fetal	O
breathing	O
and	O
aspiration	O
[	O
8	O
].	O

The	O
skin	O
has	O
innate	O
host	O
defense	O
systems	O
to	O
augment	O
barrier	O
function	O
[	O
9	O
],	O
but	O
little	O
is	O
known	O
about	O
host	O
defense	O
in	O
the	O
skin	O
of	O
the	O
preterm	O
fetus	O
,	O
which	O
in	O
early	O
gestation	O
has	O
minimal	O
cornification	O
and	O
comparatively	O
reduced	O
barrier	O
function	O
[	O
10	O
].	O

Using	O
sheep	B-OG
models	O
of	O
chorioamnionitis	B-DS
induced	O
by	O
the	O
intraamniotic	O
(	O
IA	O
)	O
administration	O
of	O
E	B-OG
.	I-OG
coli	I-OG
lipopolysaccharide	O
(	O
LPS	O
)	O
or	O
live	O
Ureaplasma	B-OG
parvum	I-OG
(	O
UP	B-OG
)	O
we	O
reported	O
that	O
the	O
fetal	O
skin	O
responded	O
with	O
increased	O
inflammatory	O
cells	O
and	O
cytokine	B-GP
expression	O
in	O
the	O
dermis	O
[	O
11	O
–	O
13	O
].	O

With	O
isolation	O
of	O
the	O
oral	O
and	O
nasal	O
epithelium	O
and	O
the	O
fetal	O
lungs	O
and	O
gut	O
,	O
an	O
intra	O
-	O
amniotic	O
exposure	O
to	O
LPS	O
induced	O
a	O
systemic	O
inflammatory	O
response	O
,	O
likely	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inflammation	O
in	O
the	O
fetal	O
skin	O
[	O
14	O
].	O

In	O
contrast	O
,	O
exposure	O
of	O
only	O
the	O
fetal	O
gut	O
did	O
not	O
induce	O
a	O
systemic	O
fetal	O
inflammatory	O
response	O
[	O
15	O
].	O

There	O
is	O
very	O
little	O
information	O
about	O
how	O
the	O
fetal	O
human	B-OG
or	O
primate	B-OG
skin	O
will	O
respond	O
to	O
chorioamnionitis	B-DS
.	O

We	O
recently	O
reported	O
that	O
intra	O
-	O
amniotic	O
injection	O
of	O
LPS	O
or	O
IL	B-GP
-	I-GP
1β	I-GP
given	O
to	O
rhesus	B-OG
macaques	I-OG
with	O
preterm	O
pregnancies	O
caused	O
acute	O
inflammation	O
in	O
the	O
decidua	O
,	O
amniotic	O
fluid	O
,	O
fetal	O
lung	O
and	O
induced	O
fetal	O
inflammatory	O
responses	O
[	O
16	O
].	O

More	O
chronic	O
exposure	O
to	O
live	O
Ureaplasma	B-OG
parvum	I-OG
caused	O
minimal	O
and	O
inconsistent	O
chorioamnionitis	B-DS
in	O
the	O
rhesus	B-OG
[	O
17	O
].	O

In	O
the	O
present	O
report	O
we	O
asked	O
if	O
the	O
fetal	O
primate	B-OG
skin	O
would	O
mount	O
a	O
proinflammatory	O
response	O
to	O
either	O
LPS	O
,	O
live	O
UP	B-OG
and	O
recombinant	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
three	O
clinically	O
relevant	O
proinflammatory	O
mediators	O
associated	O
with	O
prematurity	O
.	O

We	O
also	O
sought	O
to	O
determine	O
the	O
importance	O
of	O
IL	B-GP
-	I-GP
1	I-GP
signalling	O
to	O
a	O
putative	O
skin	O
inflammatory	O
response	O
by	O
the	O
co	O
-	O
administration	O
of	O
LPS	O
and	O
the	O
IL	B-GP
-	I-GP
1	I-GP
receptor	I-GP
antagonist	O
(	O
IL	O
-	O
1ra	O
)	O
Anakinra	O
.	O

Materials	O
and	O
methods	O

Animals	B-OG

All	O
animal	B-OG
procedures	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	B-OG
Care	O
and	O
Use	O
committee	O
at	O
the	O
University	O
of	O
California	O
,	O
Davis	O
(	O
18562	O
)	O
with	O
use	O
of	O
approved	O
standard	O
operating	O
procedures	O
for	O
Rhesus	B-OG
macaque	I-OG
(	O
Macaca	B-OG
Mulatta	I-OG
).	O

Time	O
mated	O
pregnant	O
females	O
were	O
sedated	O
with	O
ketamine	O
at	O
approximately	O
125	O
to	O
130	O
days	O
of	O
gestation	O
(	O
term	O
is	O
165	O
days	O
)	O
for	O
ultrasound	O
directed	O
IA	O
injections	O
.	O

Cesarean	O
section	O
deliveries	O
followed	O
sedation	O
and	O
pre	O
-	O
anesthesia	O
for	O
surgical	O
field	O
preparation	O
and	O
isoflurane	O
anesthesia	O
.	O

Briefly	O
,	O
dams	O
were	O
sedated	O
with	O
an	O
intramuscular	O
injection	O
of	O
ketamine	O
(	O
10	O
mg	O
/	O
kg	O
).	O

The	O
dams	O
were	O
then	O
intubated	O
,	O
connected	O
to	O
an	O
electrocardiogram	O
monitor	O
,	O
and	O
anaesthesia	O
was	O
maintained	O
with	O
inhalation	O
isofluorane	O
(	O
1	O
–	O
2	O
%	O
fresh	O
gas	O
flow	O
).	O

Intravenous	O
crystalloid	O
solution	O
(	O
0	O
.	O
9	O
%	O
NaCl	O
)	O
was	O
provided	O
at	O
a	O
rate	O
of	O
10	O
mL	O
/	O
kg	O
/	O
hour	O
.	O

Heart	O
rate	O
,	O
respiratory	O
rate	O
,	O
oxygen	O
saturation	O
,	O
and	O
depth	O
of	O
anaesthesia	O
(	O
jaw	O
tone	O
,	O
corneal	O
and	O
palpebral	O
reflexes	O
,	O
limb	O
withdrawal	O
reflex	O
)	O
were	O
constantly	O
monitored	O
during	O
the	O
procedure	O
.	O

The	O
fetus	O
was	O
removed	O
in	O
cull	O
for	O
recovery	O
of	O
gestational	O
tissues	O
and	O
amniotic	O
fluid	O
,	O
and	O
euthanized	O
with	O
intravenous	O
pentobarbital	O
.	O

The	O
dam	O
then	O
received	O
an	O
intramuscular	O
injection	O
of	O
atropine	O
(	O
0	O
.	O
04	O
mg	O
/	O
kg	O
).	O

Anaesthesia	O
was	O
withdrawn	O
at	O
the	O
end	O
of	O
the	O
procedure	O
and	O
dams	O
were	O
recovered	O
with	O
supplemental	O
oxygen	O
provided	O
until	O
airway	O
control	O
was	O
regained	O
.	O

The	O
dam	O
’	O
s	O
appetite	O
,	O
hydration	O
,	O
stool	O
quality	O
,	O
pain	O
score	O
,	O
and	O
incision	O
site	O
appearance	O
was	O
observed	O
and	O
recorded	O
postoperatively	O
for	O
at	O
least	O
seven	O
days	O
.	O

Intramuscular	O
oxymorphone	O
(	O
0	O
.	O
15	O
mg	O
/	O
kg	O
;	O
administered	O
between	O
one	O
and	O
three	O
times	O
each	O
day	O
)	O
was	O
provided	O
under	O
veterinary	O
direction	O
based	O
on	O
clinical	O
need	O
.	O

The	O
treatments	O
were	O
as	O
follows	O
:	O

LPS	O
:	O
LPS	O
(	O
1mg	O
,	O
E	B-OG
.	I-OG
coli	I-OG
O55	O
:	O
B5	O
,	O
Sigma	O
Aldrich	O
,	O
Saint	O
Louis	O
,	O
MO	O
)	O
in	O
1	O
mL	O
of	O
sterile	O
saline	O
solution	O
was	O
given	O
by	O
ultrasound	O
-	O
guided	O
IA	O
injection	O
.	O

After	O
either	O
16	O
or	O
48	O
hours	O
,	O
fetuses	O
were	O
surgically	O
delivered	O
for	O
fetal	O
tissue	O
collection	O
;	O

Ureaplasma	B-OG
:	O
Rhesus	B-OG
macaque	I-OG
dams	O
were	O
injected	O
intra	O
-	O
amniotically	O
with	O
107	O
CFU	O
Ureaplasma	B-OG
parvum	I-OG
(	O
UP	B-OG
)	O
serovar	O
1	O
[	O
17	O
]	O
under	O
ultrasound	O
gudiance	O
.	O

Fetuses	O
were	O
delivered	O
surgically	O
either	O
3	O
or	O
7	O
days	O
later	O
;	O

IL	B-GP
-	I-GP
1β	I-GP
:	O
Rhesus	B-OG
macaque	I-OG
dams	O
received	O
10	O
μg	O
human	B-OG
recombinant	O
IL	B-GP
-	I-GP
1β	I-GP
(	O
Peprotech	O
,	O
Rockyhill	O
,	O
NJ	O
)	O
in	O
1	O
ml	O
sterile	O
saline	O
or	O
1	O
ml	O
sterile	O
saline	O
by	O
ultrasound	O
guided	O
intra	O
-	O
amniotic	O
injection	O
[	O
16	O
]	O
and	O
were	O
delivered	O
either	O
1	O
or	O
3	O
days	O
later	O
;	O
and	O

LPS	O
and	O
IL	O
-	O
1ra	O
:	O
LPS	O
(	O
1mg	O
,	O
E	B-OG
.	I-OG
coli	I-OG
O55	O
:	O
B5	O
,	O
Sigma	O
Aldrich	O
,	O
Saint	O
Louis	O
,	O
MO	O
)	O
in	O
1	O
mL	O
of	O
sterile	O
saline	O
solution	O
was	O
given	O
by	O
ultrasound	O
-	O
guided	O
IA	O
injection	O
.	O

50mg	O
IA	O
and	O
100mg	O
subcutaneous	O
(	O
SC	O
)	O
IL	O
-	O
1ra	O
(	O
Anakinra	O
Sobi	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
was	O
given	O
to	O
pregnant	O
monkeys	B-OG
at	O
1	O
and	O
3	O
hours	O
,	O
respectively	O
before	O
IA	O
LPS	O
administration	O
.	O

Fetuses	O
were	O
surgically	O
delivered	O
for	O
fetal	O
tissue	O
collection	O
after	O
either	O
16	O
or	O
48	O
hours	O
.	O

The	O
variation	O
in	O
time	O
to	O
delivery	O
between	O
groups	O
reflects	O
the	O
difference	O
in	O
the	O
nature	O
of	O
the	O
anticipated	O
inflammatory	O
response	O
generated	O
by	O
different	O
agonists	O
,	O
and	O
to	O
assess	O
inflammatory	O
responses	O
at	O
acute	O
and	O
also	O
longer	O
-	O
term	O
time	O
points	O
.	O

Animals	B-OG
that	O
were	O
delivered	O
48	O
hours	O
after	O
IA	O
LPS	O
received	O
a	O
second	O
IA	O
+	O
SC	O
IL	O
-	O
1ra	O
treatment	O
,	O
administered	O
24	O
hours	O
after	O
the	O
first	O
treatment	O
.	O

Matched	O
saline	O
controls	O
were	O
established	O
for	O
each	O
of	O
the	O
four	O
treatment	O
groups	O
.	O

Samples	O
of	O
skin	O
from	O
the	O
groin	O
were	O
fixed	O
in	O
10	O
%	O
formalin	O
for	O
histological	O
analysis	O
,	O
or	O
snap	O
frozen	O
in	O
liquid	O
nitrogen	O
for	O
mRNA	O
studies	O
.	O

mRNA	O
quantitation	O

Total	O
RNA	O
was	O
isolated	O
from	O
frozen	O
skin	O
samples	O
by	O
homogenization	O
with	O
TRIzol	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
and	O
column	O
purification	O
with	O
RNeasy	O
Universal	O
Mini	O
Kits	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Reverse	O
transcription	O
was	O
performed	O
using	O
Verso	O
cDNA	O
kit	O
(	O
Thermo	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
).	O

The	O
relative	O
expression	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
1α	I-GP
,	O
IL	B-GP
-	I-GP
17α	I-GP
and	O
monocyte	B-GP
chemoattractant	I-GP
protein	I-GP
1	I-GP
(	O
MCP	B-GP
-	I-GP
1	I-GP
)	O
was	O
determined	O
by	O
rt	O
-	O
PCR	O
using	O
the	O
cDNA	O
template	O
and	O
rhesus	B-OG
macaque	I-OG
-	O
specific	O
Taqman	O
probes	O
and	O
primers	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
).	O

The	O
mRNA	O
expression	O
for	O
each	O
gene	O
was	O
normalized	O
to	O
the	O
mRNA	O
for	O
the	O
18s	O
ribosomal	O
protein	O
as	O
the	O
endogenous	O
control	O
and	O
a	O
sample	O
from	O
the	O
control	O
group	O
was	O
used	O
as	O
a	O
calibrator	O
.	O

Data	O
are	O
expressed	O
as	O
fold	O
increase	O
over	O
the	O
mean	O
control	O
value	O
.	O

Probe	O
and	O
primer	O
set	O
details	O
are	O
presented	O
in	O
Table	O
1	O
.	O

Summary	O
of	O
PCR	O
sets	O
.	O

TaqMan	O
Probe	O

Assay	O
ID	O
(	O
Applied	O
Biosystems	O
)	O

Entrez	O
Gene	O
ID	O

IL	B-GP
-	I-GP
1β	I-GP

Rh02621711_m1	O

704701	O

IL	B-GP
-	I-GP
6	I-GP

Rh02789322_m1	O

705819	O

IL	B-GP
-	I-GP
8	I-GP

Rh02789781_m1	O

613028	O

TNF	O

Rh02789783_m1	O

715467	O

IL	B-GP
-	I-GP
10	I-GP

Rh00961619_m1	O

694931	O

IL	B-GP
-	I-GP
1α	I-GP

Rh02789770_m1	O

700193	O

IL	O
-	O
17A	O

Rh02621750_m1	O

708123	O

MCP	B-GP
-	I-GP
1	I-GP

Rh02621753_m1	O

574138	O

Immunohistochemistry	O

Immunohistochemistry	O
was	O
performed	O
with	O
5	O
μm	O
thick	O
sections	O
of	O
formalin	O
fixed	O
tissues	O
.	O

Sections	O
were	O
de	O
-	O
paraffinized	O
and	O
rehydrated	O
before	O
microwave	O
-	O
assisted	O
antigen	O
retrieval	O
in	O
citric	O
acid	O
buffer	O
at	O
pH	O
6	O
.	O
0	O
.	O

Endogenous	O
peroxidase	B-GP
activity	O
was	O
reduced	O
with	O
CH3OH	O
/	O
H2O2	O
treatment	O
and	O
the	O
tissue	O
was	O
blocked	O
with	O
4	O
%	O
normal	O
goat	B-OG
serum	O
in	O
PBS	O
.	O

Sections	O
were	O
incubated	O
overnight	O
at	O
4	O
°	O
C	O
with	O
the	O
primary	O
antibody	O
diluted	O
in	O
4	O
%	O
serum	O
in	O
PBS	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
anti	O
-	O
myeloperoxidase	B-GP
(	O
MPO	B-GP
,	O
Cell	O
Marque	O
289A	O
-	O
75	O
,	O
cat	O
.	O
#	O
1404306A	O
,	O
dilution	O
1	O
:	O
200	O
),	O
anti	O
-	O
CD3	B-GP
(	O
Dako	O
Cytomation	O
,	O
A0452	O
cat	O
.	O
#	O
20024875	O
,	O
dilution	O
,	O
1	O
:	O
100	O
),	O
anti	O
-	O
CD	B-GP
68	I-GP
(	O
Biosciences	O
Pharmingen	O
,	O
M0814	O
,	O
cat	O
.	O
#	O
24648	O
,	O
dilution	O
1	O
:	O
200	O
),	O
anti	O
-	O
IL	B-GP
-	I-GP
8	I-GP
(	O
BD	O
Bioscience	O
,	O
cat	O
.	O
#	O
550419	O
,	O
dilution	O
,	O
1	O
:	O
100	O
),	O
anti	O
-	O
IL	B-GP
-	I-GP
6	I-GP
(	O
Lifespan	O
Bioscience	O
,	O
Inc	O
.	O

LS	O
-	O
B7482	O
cat	O
.	O
#	O
37847	O
,	O
dilution	O
,	O
1	O
:	O
400	O
)	O
and	O
Anti	O
-	O
Pancytokeratin	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
SC	O
-	O
81714	O
,	O
cat	O
.	O
#	O
B1015	O
,	O
dilution	O
,	O
1	O
:	O
2500	O
),	O
with	O
dilutions	O
made	O
in	O
4	O
%	O
normal	O
goat	B-OG
serum	O
.	O

Sections	O
were	O
then	O
washed	O
and	O
incubated	O
with	O
the	O
appropriate	O
species	O
-	O
specific	O
secondary	O
antibody	O
diluted	O
1	O
:	O
200	O
in	O
4	O
%	O
serum	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

After	O
further	O
washing	O
,	O
antigen	O
:	O
antibody	O
complexes	O
were	O
visualized	O
using	O
a	O
Vectastain	O
ABC	O
peroxidase	B-GP
kit	O
(	O
Vector	O
Laboratories	O
Inc	O
.,	O
Burlingame	O
,	O
CA	O
).	O

Antigen	O
detection	O
was	O
enhanced	O
with	O
nickel	O
-	O
diaminobenzidine	O
,	O
followed	O
by	O
incubation	O
with	O
Tris	O
-	O
1	O
-	O
cobalt	O
.	O

Slides	O
were	O
counterstained	O
with	O
Nuclear	O
Fast	O
Red	O
for	O
photomicroscopy	O
.	O

Blinded	O
digital	O
images	O
of	O
the	O
fetal	O
rhesus	B-OG
skin	O
(	O
5	O
non	O
-	O
overlapping	O
,	O
random	O
fields	O
per	O
animal	B-OG
)	O
were	O
quantified	O
for	O
the	O
total	O
number	O
of	O
inflammatory	O
cells	O
,	O
and	O
immunostaining	O
for	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
neutrophil	O
(	O
MPO	B-GP
),	O
monocyte	O
/	O
macrophage	O
(	O
CD68	B-GP
),	O
and	O
T	O
-	O
cells	O
(	O
CD3	B-GP
).	O

Pancytokeratin	O
staining	O
intensity	O
was	O
also	O
quantified	O
by	O
a	O
blinded	O
investigator	O
,	O
based	O
on	O
color	O
threshold	O
and	O
expressed	O
as	O
percentage	O
of	O
intense	O
,	O
moderate	O
and	O
no	O
staining	O
area	O
relative	O
to	O
total	O
area	O
.	O

Cell	O
counting	O

Sections	O
stained	O
for	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
CD3	B-GP
(	O
T	O
-	O
cells	O
),	O
CD68	B-GP
and	O
MPO	B-GP
were	O
counted	O
for	O
number	O
of	O
positive	O
cells	O
in	O
ten	O
randomly	O
-	O
selected	O
fields	O
per	O
animal	B-OG
on	O
photomicrographs	O
(	O
40x	O
objective	O
magnification	O
)	O
from	O
the	O
epidermal	O
to	O
dermal	O
layers	O
by	O
an	O
investigator	O
blinded	O
to	O
treatment	O
groups	O
.	O

A	O
similar	O
strategy	O
was	O
used	O
to	O
determine	O
the	O
percentage	O
of	O
cells	O
positively	O
stained	O
for	O
pancytokeratin	O
(	O
1	O
:	O
2	O
,	O
500	O
),	O
to	O
determine	O
both	O
the	O
number	O
and	O
the	O
percentage	O
cells	O
with	O
either	O
intense	O
,	O
moderate	O
or	O
no	O
staining	O
.	O

Statistical	O
analyses	O

GraphPad	O
Prism	O
(	O
GraphPad	O
Software	O
5	O
.	O
Ink	O
,	O
La	O
Jolla	O
,	O
CA	O
)	O
was	O
used	O
to	O
graph	O
and	O
analyze	O
data	O
for	O
statistical	O
significance	O
.	O

Data	O
are	O
presented	O
as	O
means	O
±	O
SEM	O
(	O
standard	O
error	O
of	O
the	O
mean	O
).	O

Data	O
were	O
tested	O
for	O
normality	O
and	O
variance	O
;	O
statistical	O
differences	O
between	O
groups	O
were	O
analyzed	O
using	O
Mann	O
–	O
Whitney	O
U	O
tests	O
.	O

Values	O
of	O
p	O
<	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

Results	O

Animals	B-OG

There	O
was	O
no	O
preterm	O
labor	O
or	O
evident	O
abnormalities	O
in	O
animals	B-OG
from	O
either	O
the	O
four	O
treatment	O
groups	O
or	O
matched	O
saline	O
controls	O
.	O

Gestational	O
ages	O
at	O
birth	O
and	O
birth	O
weights	O
were	O
similar	O
among	O
the	O
animals	B-OG
(	O
Table	O
2	O
).	O

Mean	O
fetal	O
weights	O
at	O
tissue	O
collection	O
were	O
not	O
different	O
between	O
groups	O
.	O

Treatment	O
groups	O
Intra	O
-	O
amniotic	O
injections	O
of	O
LPS	O
,	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
and	O
Ureaplasma	B-OG
parvum	I-OG
(	O
UP	B-OG
)	O
or	O
saline	O
were	O
performed	O
in	O
multiparous	O
macaques	B-OG
of	O
similar	O
weight	O
and	O
age	O
.	O

Separate	O
animals	B-OG
were	O
used	O
for	O
controls	O
for	O
each	O
treatment	O
group	O
.	O

Mean	O
fetal	O
weights	O
at	O
tissue	O
collection	O
were	O
not	O
different	O
between	O
groups	O
.	O

Treatment	O

N	O

Gestational	O
age	O
(	O
days	O
)	O

Birth	O
Weight	O
(	O
gm	O
)	O

Sex	O
(	O
M	O
:	O
F	O
)	O

LPS	O
and	O
IL	O
-	O
1ra	O
treatment	O

Saline	O
Control	O

13	O

132	O
±	O
0	O
.	O
6	O

337	O
±	O
8	O

6	O
:	O
7	O

LPS	O
-	O
16h	O

11	O

132	O
±	O
0	O
.	O
7	O

326	O
±	O
12	O

6	O
:	O
5	O

LPS	O
-	O
48h	O

8	O

132	O
±	O
0	O
.	O
8	O

320	O
±	O
10	O

1	O
:	O
7	O

LPS	O
and	O
IL	O
-	O
1ra	O
-	O
16h	O

6	O

132	O
±	O
1	O
.	O
5	O

354	O
±	O
14	O

3	O
:	O
3	O

LPS	O
and	O
IL	O
-	O
1ra	O
-	O
48h	O

3	O

128	O
±	O
0	O
.	O
8	O

315	O
±	O
9	O

3	O
:	O
0	O

IL	B-GP
-	I-GP
1β	I-GP
treatment	O

Saline	O
Control	O

5	O

131	O
±	O
1	O
.	O
1	O

310	O
±	O
9	O

0	O
:	O
5	O

IL	B-GP
-	I-GP
1β	I-GP
-	O
1d	O

5	O

130	O
±	O
0	O
.	O
7	O

341	O
±	O
13	O

3	O
:	O
2	O

IL	B-GP
-	I-GP
1β	I-GP
-	O
3d	O

4	O

129	O
±	O
0	O
.	O
3	O

346	O
±	O
38	O

1	O
:	O
4	O

UP	B-OG
treatment	O

Saline	O
Control	O

5	O

132	O
±	O
0	O
.	O
9	O

343	O
±	O
4	O

3	O
:	O
2	O

UP	B-OG
-	O
3d	O

5	O

130	O
±	O
1	O
.	O
1	O

348	O
±	O
19	O

2	O
:	O
3	O

UP	B-OG
-	O
7d	O

5	O

130	O
±	O
0	O
.	O
5	O

341	O
±	O
8	O

2	O
:	O
3	O

IA	O
LPS	O
,	O
UP	B-OG
but	O
not	O
IL	B-GP
-	I-GP
1β	I-GP
increase	O
cytokine	B-GP
expression	O
in	O
the	O
fetal	O
rhesus	B-OG
skin	O

IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
mRNA	O
significantly	O
increased	O
16	O
hours	O
after	O
IA	O
LPS	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Only	O
IL	B-GP
-	I-GP
8	I-GP
mRNA	O
remained	O
significantly	O
elevated	O
48h	O
after	O
LPS	O
exposure	O
(	O
Fig	O
1	O
,	O
panels	O
a	O
-	O
c	O
).	O

The	O
cytokines	B-GP
TNF	B-GP
-	I-GP
α	I-GP
,	O
IL	B-GP
-	I-GP
1α	I-GP
,	O
and	O
MCP	B-GP
-	I-GP
1	I-GP
did	O
not	O
change	O
with	O
LPS	O
exposure	O
,	O
and	O
IL	B-GP
-	I-GP
10	I-GP
was	O
undetectable	O
in	O
association	O
with	O
LPS	O
exposure	O
.	O

In	O
the	O
UP	B-OG
treatment	O
group	O
,	O
IL	B-GP
-	I-GP
1β	I-GP
mRNA	O
was	O
significantly	O
increased	O
by	O
25	O
-	O
fold	O
at	O
3	O
days	O
and	O
IL	B-GP
-	I-GP
6	I-GP
mRNA	O
increased	O
by	O
5	O
-	O
fold	O
at	O
7	O
days	O
after	O
IA	O
UP	B-OG
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Fig	O
1	O
,	O
panels	O
a	O
and	O
b	O
).	O

In	O
contrast	O
to	O
LPS	O
exposure	O
,	O
TNF	B-GP
-	I-GP
α	I-GP
increased	O
significantly	O
15	O
fold	O
at	O
3	O
days	O
and	O
9	O
fold	O
at	O
7	O
days	O
,	O
but	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
1α	I-GP
,	O
and	O
MCP	B-GP
-	I-GP
1	I-GP
did	O
not	O
change	O
with	O
UP	B-OG
exposure	O
(	O
Table	O
3	O
).	O

IL	B-GP
-	I-GP
1β	I-GP
treatment	O
did	O
not	O
significantly	O
increase	O
the	O
mRNA	O
expression	O
of	O
any	O
of	O
the	O
cytokines	B-GP
or	O
chemokines	B-GP
measured	O
at	O
either	O
time	O
point	O
.	O

Cytokine	B-GP
PCR	O
Analysis	O
.	O

Quantitative	O
PCR	O
analysis	O
of	O
cytokines	B-GP
in	O
fetal	O
rhesus	B-OG
macaque	I-OG
skin	O
following	O
intra	O
-	O
amniotic	O
exposure	O
with	O
LPS	O
,	O
IL	B-GP
-	I-GP
1β	I-GP
or	O
UP	B-OG
and	O
for	O
different	O
times	O
of	O
exposure	O
(	O
Panel	O
a	O
,	O
b	O
and	O
c	O
).	O

Cytokine	B-GP
expression	O
for	O
LPS	O
and	O
LPS	O
plus	O
IL	O
-	O
1ra	O
exposure	O
groups	O
(	O
Panel	O
d	O
,	O
e	O
and	O
f	O
).	O

Graphs	O
represent	O
mean	O
mRNA	O
fold	O
change	O
±	O
SD	O
.	O
*	O
indicates	O
a	O
significant	O
increase	O
in	O
transcript	O
expression	O
relative	O
to	O
untreated	O
control	O
group	O
normalized	O
to	O
a	O
value	O
for	O
1	O
.	O
0	O
.	O
ɸ	O
indicates	O
a	O
significant	O
decrease	O
in	O
transcript	O
expression	O
relative	O
to	O
LPS	O
at	O
16	O
hours	O
.	O

Summary	O
of	O
cytokine	B-GP
/	O
chemokine	B-GP
mRNA	O
expression	O
.	O

Data	O
are	O
mean	O
±	O
SD	O
;	O
*	O
p	O
=	O
0	O
.	O
05	O
.	O

Cells	O
without	O
data	O
represent	O
transcript	O
levels	O
below	O
limit	O
of	O
detection	O
.	O

TNF	O

IL	B-GP
-	I-GP
10	I-GP

IL	B-GP
-	I-GP
1α	I-GP

MCP	B-GP
-	I-GP
1	I-GP

Control	O

1	O
.	O
0	O
±	O
0	O
.	O
6	O

1	O
.	O
0	O
±	O
1	O
.	O
0	O

1	O
.	O
0	O
±	O
0	O
.	O
8	O

1	O
.	O
0	O
±	O
0	O
.	O
9	O

LPS	O
16h	O

1	O
.	O
3	O
±	O
0	O
.	O
8	O

-	O

2	O
.	O
5	O
±	O
3	O
.	O
9	O

1	O
.	O
4	O
±	O
0	O
.	O
8	O

LPS	O
+	O
IL	O
-	O
1RA	O
16h	O

1	O
.	O
2	O
±	O
0	O
.	O
6	O

-	O

1	O
.	O
8	O
±	O
1	O
.	O
4	O

1	O
.	O
8	O
±	O
0	O
.	O
6	O

LPS	O
48h	O

3	O
.	O
1	O
±	O
5	O
.	O
7	O

-	O

1	O
.	O
3	O
±	O
0	O
.	O
8	O

1	O
.	O
0	O
±	O
0	O
.	O
8	O

LPS	O
+	O
IL	O
-	O
1RA	O
48h	O

3	O
.	O
3	O
±	O
3	O
.	O
4	O

-	O

3	O
.	O
7	O
±	O
3	O
.	O
2	O

1	O
.	O
2	O
±	O
0	O
.	O
6	O

IL	B-GP
-	I-GP
1B	I-GP
1d	O

1	O
.	O
7	O
±	O
1	O
.	O
4	O

2	O
.	O
3	O
±	O
2	O
.	O
6	O

1	O
.	O
7	O
±	O
1	O
.	O
7	O

0	O
.	O
7	O
±	O
0	O
.	O
3	O

IL	B-GP
-	I-GP
1B	I-GP
3d	O

1	O
.	O
1	O
±	O
0	O
.	O
5	O

0	O
.	O
6	O
±	O
0	O
.	O
3	O

0	O
.	O
7	O
±	O
0	O
.	O
3	O

0	O
.	O
3	O
±	O
0	O
.	O
1	O

UP	B-OG
3d	O

15	O
.	O
0	O
±	O
29	O
.	O
6	O
*	O

-	O

1	O
.	O
4	O
±	O
1	O
.	O
0	O

2	O
.	O
4	O
±	O
2	O
.	O
6	O

UP	B-OG
7d	O

9	O
.	O
0	O
±	O
8	O
.	O
9	O
*	O

-	O

1	O
.	O
2	O
±	O
0	O
.	O
5	O

2	O
.	O
7	O
±	O
2	O
.	O
1	O

IL	O
-	O
1ra	O
decreased	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
mRNA	O
expression	O
in	O
LPS	O
exposed	O
fetal	O
rhesus	B-OG
skin	O

In	O
the	O
LPS	O
+	O
IL	O
-	O
1ra	O
treatment	O
group	O
,	O
there	O
were	O
statistically	O
significant	O
decreases	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
mRNA	O
expression	O
at	O
16	O
hours	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Fig	O
1	O
,	O
panels	O
d	O
and	O
f	O
)	O
relative	O
to	O
LPS	O
-	O
treatment	O
only	O
.	O

IA	O
LPS	O
and	O
the	O
impact	O
of	O
IA	O
IL	O
-	O
1ra	O
on	O
inflammatory	O
mediators	O

We	O
performed	O
immunohistochemistry	O
(	O
IHC	O
)	O
for	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
8	I-GP
,	O
CD3	B-GP
,	O
CD68	B-GP
,	O
MPO	B-GP
and	O
pancytokeratin	O
.	O

The	O
number	O
of	O
cells	O
positively	O
stained	O
for	O
IL	B-GP
-	I-GP
6	I-GP
and	O
pancytokeratin	O
increased	O
significantly	O
16	O
hours	O
after	O
IA	O
LPS	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Figs	O
2	O
and	O
3	O
).	O

We	O
did	O
not	O
identify	O
changes	O
in	O
the	O
other	O
markers	O
assessed	O
.	O

The	O
administration	O
of	O
IL	O
-	O
1ra	O
significantly	O
decreased	O
the	O
number	O
of	O
IL	B-GP
-	I-GP
6	I-GP
positive	O
cells	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Fig	O
2	O
).	O

There	O
was	O
a	O
significant	O
increase	O
in	O
the	O
percentage	O
of	O
intensely	O
positive	O
pancytokeratin	O
stained	O
cells	O
for	O
the	O
LPS	O
group	O
at	O
16	O
hours	O
relative	O
to	O
the	O
untreated	O
control	O
group	O
.	O

At	O
16	O
hours	O
,	O
there	O
was	O
significant	O
decrease	O
in	O
the	O
percent	O
of	O
intense	O
positive	O
cell	O
after	O
IA	O
IL	O
-	O
1ra	O
administration	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Fig	O
3	O
).	O

There	O
was	O
no	O
difference	O
in	O
moderate	O
staining	O
of	O
pancytokeratin	O
IHC	O
between	O
groups	O
.	O

We	O
did	O
not	O
observe	O
infiltrating	O
neutrophils	O
(	O
MPO	B-GP
),	O
leukocytes	O
(	O
CD3	B-GP
+)	O
or	O
infiltrating	O
macrophages	O
(	O
CD68	B-GP
+)	O
in	O
fetal	O
skin	O
after	O
IA	O
LPS	O
treatment	O
.	O

IL	B-GP
-	I-GP
6	I-GP
expression	O
.	O

Representative	O
photomicrographs	O
for	O
IL	B-GP
-	I-GP
6	I-GP
(	O
1	O
:	O
400	O
)	O
immunohistochemical	O
staining	O
of	O
fetal	O
skin	O
.	O

(	O
A	O
)	O
control	O
;	O
(	O
B	O
)	O
LPS	O
at	O
16	O
h	O
;	O
(	O
C	O
)	O
LPS	O
and	O
IL	O
-	O
1ra	O
at	O
16	O
h	O
exposure	O
.	O

(	O
D	O
)	O
The	O
number	O
of	O
positive	O
cells	O
(	O
arrow	O
),	O
that	O
were	O
counted	O
between	O
groups	O
.	O

(	O
magnification	O
bar	O
represents	O
20	O
μm	O
).	O
*	O
indicates	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
positive	O
cells	O
relative	O
to	O
the	O
untreated	O
control	O
.	O
ɸ	O
indicates	O
a	O
significant	O
decrease	O
in	O
number	O
of	O
positive	O
cells	O
relative	O
to	O
LPS	O
.	O

Pancytokeratin	O
expression	O
.	O

Representative	O
photomicrographs	O
for	O
pancytokeratin	O
(	O
1	O
:	O
2500	O
)	O
immunohistochemical	O
staining	O
of	O
fetal	O
skin	O
.	O

(	O
A	O
)	O
control	O
;	O
(	O
B	O
)	O
LPS	O
at	O
16	O
h	O
;	O
(	O
C	O
)	O
LPS	O
and	O
IL	O
-	O
1ra	O
at	O
16	O
h	O
exposure	O
.	O

(	O
D	O
)	O
Graph	O
shows	O
the	O
comparison	O
between	O
groups	O
in	O
the	O
percent	O
of	O
positive	O
cells	O
of	O
different	O
intensity	O
stain	O
;	O
intense	O
(	O
arrow	O
),	O
moderate	O
and	O
no	O
stain	O
(	O
magnification	O
bar	O
represents	O
20	O
μm	O
).	O
*	O
indicates	O
a	O
significant	O
difference	O
in	O
the	O
percent	O
of	O
positive	O
cell	O
between	O
LPS	O
at	O
16	O
hours	O
and	O
untreated	O
control	O
group	O
.	O
ɸ	O
indicates	O
a	O
significant	O
difference	O
in	O
the	O
percent	O
of	O
positive	O
cell	O
between	O
LPS	O
group	O
and	O
LPS	O
plus	O
IL	O
-	O
1ra	O
group	O
at	O
16	O
hours	O
.	O

Discussion	O

We	O
demonstrate	O
that	O
the	O
fetal	O
rhesus	B-OG
skin	O
is	O
capable	O
of	O
generating	O
an	O
inflammatory	O
response	O
in	O
utero	O
,	O
in	O
response	O
to	O
direct	O
stimulation	O
by	O
both	O
LPS	O
and	O
UP	B-OG
.	O

In	O
LPS	O
-	O
exposed	O
animals	B-OG
,	O
we	O
show	O
that	O
this	O
response	O
involves	O
increased	O
expression	O
of	O
mRNA	O
transcripts	O
for	O
preterm	O
birth	O
-	O
associated	O
proinflammatory	O
cytokines	B-GP
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
and	O
IL	B-GP
-	I-GP
8	I-GP
,	O
and	O
increased	O
staining	O
for	O
IL	B-GP
-	I-GP
6	I-GP
and	O
pancytokeratin	O
in	O
the	O
skin	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
previous	O
reports	O
of	O
increased	O
expression	O
of	O
cytokeratin	B-GP
following	O
stimulation	O
of	O
keratinocytes	O
with	O
pro	O
-	O
inflammatory	O
cytokines	B-GP
[	O
18	O
].	O

IA	O
UP	B-OG
-	O
treatment	O
resulted	O
in	O
increased	O
IL	B-GP
-	I-GP
1β	I-GP
mRNA	O
expression	O
at	O
3d	O
post	O
-	O
treatment	O
and	O
increased	O
IL	B-GP
-	I-GP
6	I-GP
expression	O
at	O
7d	O
post	O
-	O
treatment	O
.	O

Although	O
these	O
studies	O
were	O
not	O
designed	O
to	O
accurately	O
determine	O
the	O
ontogeny	O
of	O
skin	O
responses	O
to	O
inflammatory	O
agonist	O
,	O
it	O
is	O
apparent	O
that	O
the	O
skin	O
is	O
able	O
to	O
rapidly	O
mount	O
an	O
inflammatory	O
response	O
to	O
microbial	O
agonist	O
and	O
,	O
that	O
in	O
the	O
case	O
of	O
UP	B-OG
,	O
this	O
response	O
persists	O
for	O
an	O
extended	O
period	O
.	O

In	O
our	O
experimental	O
system	O
it	O
is	O
not	O
possible	O
to	O
isolate	O
the	O
impact	O
of	O
systemic	O
vs	O
direct	O
agonist	O
inflammatory	O
stimulation	O
on	O
the	O
fetal	O
skin	O
.	O

IA	O
administration	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
alone	O
was	O
not	O
associated	O
with	O
pro	O
-	O
inflammatory	O
changes	O
in	O
the	O
fetal	O
skin	O
.	O

However	O
,	O
the	O
co	O
-	O
administration	O
of	O
IL	O
-	O
1ra	O
with	O
LPS	O
was	O
associated	O
with	O
significant	O
reductions	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
and	O
IL	B-GP
-	I-GP
8	I-GP
transcript	O
expression	O
,	O
in	O
the	O
number	O
of	O
IL	B-GP
-	I-GP
6	I-GP
positive	O
cells	O
in	O
the	O
dermis	O
,	O
and	O
in	O
the	O
intensity	O
pancytokeratin	O
staining	O
relative	O
to	O
LPS	O
-	O
treatment	O
only	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
both	O
LPS	O
and	O
UP	B-OG
can	O
induce	O
fetal	O
skin	B-DS
inflammation	I-DS
,	O
and	O
,	O
given	O
that	O
LPS	O
-	O
driven	O
inflammatory	O
responses	O
are	O
partially	O
blocked	O
with	O
IA	O
IL	O
-	O
1ra	O
therapy	O
,	O
that	O
IL	B-GP
-	I-GP
1	I-GP
signaling	O
likely	O
plays	O
an	O
important	O
role	O
in	O
skin	B-DS
inflammation	I-DS
in	O
utero	O
.	O

Infection	B-DS
of	O
amniotic	O
fluid	O
results	O
in	O
the	O
production	O
of	O
proinflammatory	O
cytokines	B-GP
and	O
chemokines	B-GP
[	O
19	O
,	O
20	O
].	O

The	O
fetal	O
skin	O
,	O
which	O
has	O
a	O
large	O
surface	O
area	O
,	O
is	O
entirely	O
exposed	O
to	O
the	O
amniotic	O
fluid	O
containing	O
any	O
invading	O
microorganisms	O
and	O
proinflammatory	O
agonists	O
.	O

Important	O
questions	O
that	O
remain	O
unanswered	O
are	O
the	O
relative	O
importance	O
of	O
maternal	O
or	O
fetal	O
inflammation	O
,	O
and	O
which	O
tissues	O
(	O
chorioamnion	O
,	O
placenta	O
,	O
fetal	O
lung	O
or	O
fetal	O
skin	O
)	O
are	O
primarily	O
responsible	O
for	O
initiating	O
the	O
fetal	O
inflammatory	O
responses	O
.	O

We	O
suggest	O
that	O
the	O
developing	O
fetal	O
skin	O
may	O
contribute	O
to	O
the	O
acute	O
fetal	O
inflammatory	O
response	O
(	O
FIRS	O
),	O
which	O
is	O
associated	O
with	O
preterm	O
birth	O
and	O
adverse	O
neonatal	O
outcomes	O
.	O

Even	O
a	O
limited	O
inflammatory	O
fetal	O
skin	O
response	O
could	O
have	O
systemic	O
effects	O
on	O
the	O
fetus	O
due	O
to	O
a	O
large	O
surface	O
area	O
and	O
the	O
high	O
degree	O
of	O
vascularization	O
.	O

We	O
previously	O
showed	O
in	O
fetal	O
sheep	B-OG
that	O
chorioamnionitis	B-DS
caused	O
by	O
the	O
intra	O
-	O
amniotic	O
injection	O
of	O
LPS	O
resulted	O
in	O
inflammation	O
,	O
particularly	O
of	O
the	O
fetal	O
lung	O
,	O
gut	O
,	O
skin	O
,	O
and	O
chorioamnion	O
[	O
13	O
,	O
21	O
,	O
22	O
].	O

IL	B-GP
-	I-GP
1	I-GP
was	O
central	O
to	O
this	O
inflammation	O
as	O
blockade	O
of	O
IL	B-GP
-	I-GP
1	I-GP
signaling	O
in	O
the	O
amniotic	O
compartment	O
with	O
the	O
same	O
recombinant	O
IL	B-GP
-	I-GP
1	I-GP
receptor	I-GP
antagonist	O
(	O
IL	O
-	O
1ra	O
)	O
largely	O
inhibited	O
the	O
fetal	O
lung	O
and	O
systemic	O
inflammation	O
caused	O
by	O
intra	O
-	O
amniotic	O
E	B-OG
.	I-OG
coli	I-OG
LPS	O
[	O
20	O
].	O

The	O
skin	O
inflammatory	O
response	O
to	O
UP	B-OG
were	O
modest	O
but	O
the	O
evaluation	O
was	O
3	O
and	O
7	O
days	O
after	O
IA	O
injection	O
of	O
organisms	O
.	O

We	O
anticipate	O
that	O
there	O
would	O
be	O
a	O
longer	O
interval	O
from	O
IA	O
injection	O
to	O
an	O
inflammation	O
for	O
UP	B-OG
than	O
LPS	O
.	O

The	O
proinflammatory	O
cytokines	B-GP
IL	B-GP
-	I-GP
1β	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
are	O
considered	O
primary	O
mediators	O
of	O
septic	O
shock	O
and	O
are	O
also	O
associated	O
with	O
infection	B-DS
-	O
induced	O
preterm	O
delivery	O
[	O
16	O
].	O

The	O
robust	O
expression	O
of	O
IL	B-GP
-	I-GP
1	I-GP
β	I-GP
by	O
the	O
primate	B-OG
fetal	O
skin	O
in	O
response	O
to	O
IA	O
LPS	O
stimulation	O
may	O
be	O
of	O
significance	O
,	O
given	O
the	O
association	O
of	O
these	O
cytokines	B-GP
with	O
infection	B-DS
-	O
associated	O
preterm	O
labor	O
.	O

Increases	O
in	O
IL	B-GP
-	I-GP
6	I-GP
expression	O
are	O
frequently	O
identified	O
in	O
association	O
with	O
preterm	O
birth	O
.	O

IL	B-GP
-	I-GP
6	I-GP
is	O
a	O
marker	O
of	O
systemic	O
fetal	O
inflammatory	O
response	O
syndrome	O
(	O
cord	O
blood	O
IL	B-GP
-	I-GP
6	I-GP
>	O
11	O
pg	O
/	O
mL	O
)	O
[	O
2	O
,	O
6	O
,	O
19	O
].	O

In	O
the	O
present	O
study	O
,	O
IL	B-GP
-	I-GP
6	I-GP
transcript	O
expression	O
in	O
the	O
fetal	O
skin	O
was	O
increased	O
significantly	O
only	O
after	O
16	O
hours	O
of	O
LPS	O
stimulation	O
,	O
but	O
remained	O
elevated	O
7d	O
after	O
UP	B-OG
exposure	O
.	O

IL	B-GP
-	I-GP
8	I-GP
is	O
a	O
potent	O
chemotactant	O
and	O
neutrophil	O
activating	O
factor	O
which	O
is	O
part	O
of	O
the	O
response	O
elicited	O
in	O
the	O
host	O
against	O
microbial	O
invasion	O
.	O

IL	B-GP
-	I-GP
8	I-GP
also	O
can	O
recruit	O
neutrophils	O
to	O
the	O
fetal	O
membranes	O
and	O
the	O
placenta	O
during	O
the	O
development	O
of	O
an	O
intrauterine	B-DS
infection	I-DS
.	O

There	O
was	O
no	O
significant	O
change	O
in	O
IL	B-GP
-	I-GP
8	I-GP
protein	O
expression	O
in	O
response	O
to	O
UP	B-OG
administration	O
at	O
either	O
3d	O
or	O
7d	O
.	O

Although	O
IL	B-GP
-	I-GP
8	I-GP
transcript	O
expression	O
in	O
the	O
fetal	O
skin	O
was	O
increased	O
significantly	O
both	O
16	O
and	O
48	O
hours	O
post	O
-	O
LPS	O
stimulation	O
,	O
we	O
did	O
not	O
observe	O
infiltrating	O
neutrophils	O
(	O
MPO	B-GP
),	O
leukocytes	O
(	O
CD3	B-GP
+)	O
or	O
infiltrating	O
macrophages	O
(	O
CD68	B-GP
+)	O
in	O
fetal	O
rhesus	B-OG
skin	O
as	O
we	O
anticipated	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
findings	O
may	O
be	O
the	O
structural	O
immaturity	O
of	O
the	O
fetal	O
skin	O
which	O
may	O
allow	O
immunocytes	O
to	O
move	O
from	O
the	O
skin	O
to	O
the	O
amniotic	O
fluid	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
fetal	O
immunocytes	O
(	O
specifically	O
,	O
neutrophils	O
,	O
lymphocytes	O
and	O
monocytes	O
)	O
are	O
recruited	O
into	O
the	O
amniotic	O
fluid	O
[	O
22	O
].	O

After	O
IA	O
LPS	O
administration	O
,	O
immunocytes	O
isolated	O
from	O
the	O
amniotic	O
fluid	O
expressed	O
proinflammatory	O
cytokine	B-GP
mRNA	O
for	O
IL	B-GP
-	I-GP
8	I-GP
at	O
72	O
hours	O
and	O
7	O
days	O
while	O
no	O
cytokine	B-GP
mRNA	O
can	O
be	O
detected	O
in	O
the	O
chorioamnion	O
,	O
lung	O
,	O
or	O
spleen	O
after	O
72	O
hours	O
[	O
22	O
].	O

The	O
permeable	O
nature	O
of	O
the	O
developing	O
fetal	O
rhesus	B-OG
skin	O
at	O
early	O
gestation	O
may	O
be	O
permissive	O
for	O
the	O
transepidermal	O
passage	O
of	O
cytokines	B-GP
and	O
chemokines	B-GP
from	O
the	O
fetus	O
into	O
the	O
amniotic	O
fluid	O
[	O
22	O
].	O

In	O
the	O
present	O
study	O
,	O
an	O
injection	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
sufficient	O
to	O
induce	O
chorioamnionitis	B-DS
and	O
fetal	O
inflammatory	O
response	O
[	O
16	O
]	O
did	O
not	O
cause	O
skin	B-DS
inflammation	I-DS
in	O
the	O
non	O
-	O
human	B-OG
primate	B-OG
.	O

In	O
a	O
related	O
unpublished	O
observation	O
,	O
IA	O
IL	B-GP
-	I-GP
1β	I-GP
also	O
did	O
not	O
cause	O
skin	B-DS
inflammation	I-DS
in	O
sheep	B-OG
(	O
M	O
.	O

Kemp	O
,	O
Personal	O
Communication	O
).	O

This	O
observation	O
is	O
of	O
interest	O
,	O
given	O
the	O
importance	O
of	O
IL	B-GP
-	I-GP
1	I-GP
signaling	O
to	O
skin	B-DS
inflammation	I-DS
,	O
and	O
the	O
robust	O
response	O
seen	O
in	O
the	O
macaque	B-OG
fetal	O
lung	O
and	O
chorioamnion	O
in	O
response	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
stimulation	O
.	O

IL	B-GP
-	I-GP
1	I-GP
is	O
well	O
established	O
as	O
a	O
critical	O
mediator	O
of	O
skin	B-DS
inflammation	I-DS
,	O
with	O
both	O
IL	B-GP
-	I-GP
1α	I-GP
and	O
IL	B-GP
-	I-GP
1β	I-GP
acting	O
via	O
IL	B-GP
-	I-GP
1	I-GP
receptor	I-GP
1	I-GP
.	O

Enk	O
and	O
colleagues	O
,	O
for	O
example	O
,	O
have	O
proposed	O
that	O
IL	B-GP
-	I-GP
1β	I-GP
produced	O
by	O
dendritic	O
cells	O
may	O
be	O
critical	O
to	O
the	O
induction	O
of	O
skin	O
immune	O
responses	O
[	O
23	O
].	O

Dysregulation	O
of	O
the	O
IL	B-GP
-	I-GP
1α	I-GP
:	O
IL	O
-	O
1Ra	O
ratio	O
has	O
been	O
implicated	O
in	O
a	O
range	O
of	O
inflammatory	O
skin	B-DS
diseases	I-DS
including	O
psoriasis	B-DS
and	O
contact	B-DS
dermatitis	I-DS
[	O
24	O
].	O

Biologically	O
active	O
31	O
kDa	O
IL	B-GP
-	I-GP
1α	I-GP
is	O
the	O
predominant	O
form	O
expressed	O
by	O
epithelial	O
cells	O
,	O
including	O
keratinocytes	O
.	O

In	O
contrast	O
,	O
biologically	O
active	O
IL	B-GP
-	I-GP
1β	I-GP
is	O
generated	O
by	O
cleavage	O
of	O
the	O
31	O
kDa	O
inactive	O
form	O
by	O
stimulated	O
Langerhans	O
cells	O
,	O
monocytes	O
and	O
macrophages	O
.	O

Although	O
keratinocytes	O
also	O
generate	O
the	O
biologically	O
inactive	O
31kDa	O
IL	B-GP
-	I-GP
1β	I-GP
precursor	O
,	O
they	O
largely	O
lack	O
the	O
enzyme	O
necessary	O
to	O
complete	O
significant	O
post	O
-	O
translational	O
generation	O
of	O
the	O
mature	O
17	O
kDa	O
protein	O
[	O
25	O
].	O

It	O
is	O
tempting	O
to	O
speculate	O
as	O
to	O
why	O
10	O
ug	O
of	O
IA	O
IL	B-GP
-	I-GP
1β	I-GP
failed	O
to	O
elicit	O
skin	B-DS
inflammation	I-DS
in	O
the	O
macaque	B-OG
fetus	O
,	O
despite	O
being	O
associated	O
with	O
pulmonary	B-DS
inflammation	I-DS
and	O
chorioamnionitis	B-DS
.	O

Firstly	O
,	O
it	O
is	O
possible	O
that	O
there	O
was	O
insufficient	O
IL1R	B-GP
available	O
in	O
the	O
fetal	O
skin	O
to	O
drive	O
a	O
detectable	O
inflammatory	O
response	O
to	O
IL	B-GP
-	I-GP
1β	I-GP
stimulation	O
.	O

Using	O
newborn	O
human	B-OG
foreskin	O
samples	O
,	O
Groves	O
and	O
colleagues	O
demonstrated	O
that	O
in	O
contrast	O
to	O
adult	O
human	B-OG
skin	O
(	O
which	O
demonstrates	O
robust	O
basal	O
and	O
apical	O
epidermal	O
IL	B-GP
-	I-GP
1R	I-GP
staining	O
[	O
26	O
])	O
untreated	O
tissues	O
expressed	O
very	O
few	O
IL	B-GP
-	I-GP
1R	I-GP
(	O
either	O
type	O
1	O
or	O
2	O
),	O
although	O
significant	O
and	O
rapid	O
increases	O
in	O
the	O
expression	O
of	O
the	O
type	O
-	O
II	O
(	O
inhibitory	O
)	O
IL	B-GP
-	I-GP
1R	I-GP
could	O
be	O
induced	O
by	O
tissue	O
stimulation	O
with	O
interferon	B-GP
-	I-GP
ɣ	O
,	O
or	O
by	O
overnight	O
incubation	O
at	O
37	O
°	O
C	O
[	O
27	O
].	O

In	O
contrast	O
,	O
Toll	B-GP
-	I-GP
like	I-GP
receptors	I-GP
(	O
including	O
Toll	B-GP
-	I-GP
like	I-GP
receptor	I-GP
4	I-GP
,	O
which	O
is	O
strongly	O
agonized	O
by	O
LPS	O
)	O
are	O
expressed	O
in	O
skin	O
from	O
an	O
early	O
gestational	O
age	O
,	O
likely	O
facilitating	O
the	O
LPS	O
-	O
driven	O
response	O
identified	O
in	O
the	O
present	O
report	O
[	O
28	O
].	O

However	O
,	O
against	O
this	O
hypothesis	O
is	O
our	O
observation	O
that	O
IL	O
-	O
1Ra	O
was	O
able	O
to	O
antagonize	O
LPS	O
-	O
driven	O
inflammation	O
,	O
which	O
itself	O
requires	O
the	O
binding	O
of	O
IL	O
-	O
1Ra	O
to	O
type	B-GP
I	I-GP
IL	I-GP
-	I-GP
1R	I-GP
.	O

Secondly	O
,	O
it	O
is	O
possible	O
that	O
the	O
dose	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
administered	O
was	O
insufficient	O
to	O
overcome	O
inhibition	O
of	O
IL	B-GP
-	I-GP
1R1	I-GP
signaling	O
by	O
endogenously	O
expressed	O
IL1Ra	O
,	O
although	O
given	O
the	O
high	O
ration	O
of	O
IL	O
-	O
1Ra	O
:	O
IL1	B-GP
required	O
to	O
inhibit	O
productive	O
signaling	O
(	O
ranging	O
between	O
10	O
:	O
1	O
and	O
100	O
:	O
1	O
[	O
24	O
]),	O
this	O
explanation	O
also	O
seems	O
unlikely	O
.	O

Thirdly	O
,	O
it	O
is	O
possible	O
that	O
the	O
magnitude	O
of	O
inflammatory	O
response	O
generated	O
by	O
IL	B-GP
-	I-GP
1β	I-GP
stimulation	O
were	O
too	O
small	O
to	O
be	O
identified	O
statistically	O
with	O
the	O
group	O
sizes	O
used	O
in	O
our	O
study	O
.	O

Lastly	O
,	O
unlike	O
in	O
the	O
fetal	O
lung	O
,	O
it	O
is	O
possible	O
that	O
IL	B-GP
-	I-GP
1β	I-GP
-	O
driven	O
responses	O
in	O
the	O
skin	O
are	O
acute	O
,	O
modest	O
,	O
and	O
resolve	O
within	O
24h	O
.	O

There	O
are	O
a	O
number	O
of	O
clinical	O
correlations	O
of	O
this	O
study	O
.	O

In	O
chorioamnionitis	B-DS
-	O
induced	O
fetal	O
inflammatory	O
response	O
,	O
the	O
fetal	O
skin	O
may	O
contribute	O
to	O
the	O
inflammation	O
in	O
the	O
amniotic	O
fluid	O
and	O
systemically	O
.	O

Furthermore	O
,	O
skin	B-DS
inflammation	I-DS
could	O
further	O
compromise	O
the	O
already	O
poor	O
barrier	O
function	O
of	O
the	O
fetus	O
or	O
decrease	O
the	O
permeability	O
by	O
the	O
increased	O
cornification	O
.	O

Infants	O
exposed	O
to	O
chorioamnionitis	B-DS
could	O
have	O
an	O
increased	O
predisposition	O
to	O
nosocomial	B-DS
infection	I-DS
from	O
alterations	O
in	O
skin	O
barrier	O
function	O
.	O

IA	O
IL	O
-	O
1ra	O
therapy	O
can	O
block	O
the	O
inflammatory	O
responses	O
in	O
primate	B-OG
fetal	O
skin	O
and	O
FIRS	O
from	O
LPS	O
,	O
the	O
receptor	O
blockers	O
may	O
both	O
block	O
preterm	O
delivery	O
and	O
fetal	O
injury	O
.	O

In	O
conclusion	O
,	O
the	O
primate	B-OG
fetal	O
skin	O
can	O
mount	O
an	O
inflammatory	O
response	O
to	O
in	O
utero	O
inflammation	O
,	O
although	O
this	O
response	O
is	O
modest	O
and	O
appears	O
to	O
lack	O
an	O
immunocyte	O
response	O
,	O
at	O
least	O
acutely	O
.	O

However	O
,	O
given	O
the	O
size	O
,	O
degree	O
of	O
vascularization	O
,	O
and	O
direct	O
exposure	O
to	O
the	O
amniotic	O
fluid	O
,	O
the	O
primate	B-OG
fetal	O
skin	O
may	O
be	O
an	O
important	O
source	O
of	O
the	O
both	O
fetal	O
inflammation	O
and	O
pro	O
-	O
inflammatory	O
mediators	O
that	O
could	O
signal	O
the	O
chorioamnion	O
,	O
cervix	O
,	O
and	O
uterus	O
to	O
ultimately	O
induce	O
preterm	O
labor	O
.	O

